Prolexys Licenses the Prolexys Human Interactome Database to GlaxoSmithKline
News Oct 04, 2005
Prolexys Pharmaceuticals, Inc. has announced that it has completed a non-exclusive license agreement with GlaxoSmithKline for the Prolexys Human Interactome Database.
This database contains over 258,000 human protein-protein interactions, representing approximately one half of all RefSeq entries.
The dataset was built from a wide range of human cell and tissue types using the Company's HyNet™ system, a highly automated high-throughput yeast 2-hybrid process.
This system is designed to give a strong preference to high confidence interactions and the quality of the data has been demonstrated in a variety of tests.
“This asset adds significant value to state-of-the-art pharmaceutical research programs in the areas of novel target identification, target validation, improved understanding of disease biology, and efficient choice of research direction,” said Dr. Sudhir Sahasrabudhe, Chief Scientific Officer of Prolexys.
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.